<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="be0210a1-cda6-4f01-af18-5b022bbc68a5"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="Human Prescription Drug Label"/>
   <title>These highlights do not include all the information needed to use LIOTHYRONINE SODIUM TABLETS safely and effectively. See full prescribing information for LIOTHYRONINE SODIUM TABLETS.<br/>
      <br/> LIOTHYRONINE SODIUM tablets, for oral use<br/> Initial U.S. Approval: 1956</title>
   <effectiveTime value="20250312"/>
   <setId root="1d6b6f92-89e8-497a-ab23-d0afa2137d1f"/>
   <versionNumber value="1"/>
   <author>
      <assignedEntity>
         <representedOrganization>
            <id extension="830016429" root="1.3.6.1.4.1.519.1"/>
            <name>A-S Medication Solutions</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="830016429" root="1.3.6.1.4.1.519.1"/>
                        <name>A-S Medication Solutions</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" displayName="RELABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50090-7518" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="REPACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50090-7518" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="f9ed230a-5d00-4dc6-9c47-a1d9f30364d6"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20230629"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50090-7518" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>liothyronine sodium</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>liothyronine sodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="62756-589" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="5" unit="ug"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="GCA9VV7D2N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LIOTHYRONINE SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="06LU7C9H1V" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LIOTHYRONINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1T8387508X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN TYPE B BOVINE (160 BLOOM)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50090-7518-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250311"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50090-7518-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250311"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA091382" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20191128"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>White to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND">
                              <originalText>Circular</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" unit="mm" value="7"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">589</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_0">
               <id root="2ec94405-5642-4c77-9996-8c6ea2cb721c"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS</title>
               <text>
                  <list listType="unordered" styleCode="disc">
                     <item>Thyroid hormones, including liothyronine sodium tablets, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss.</item>
                     <item>In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.</item>
                     <item>Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects <content styleCode="italics">[see Adverse Reactions (6), Drug Interactions (7.7), and Overdosage (10)].</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20231003"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Thyroid hormones, including liothyronine sodium tablets, should not be used for the treatment of obesity or for weight loss.</content>
                           </item>
                           <item>
                              <content styleCode="bold">Doses beyond the range of daily hormonal requirements may produce serious or even life-threatening manifestations of toxicity (6, 7.7, 10).</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="5566fe4b-946f-4dc3-9523-05d7b8e49aa6"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20210624"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Liothyronine is an L-triiodothyronine (T3) indicated for:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism (1.1)</item>
                           <item>Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer (1.2)</item>
                           <item>Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy (1.3)</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. (1)</item>
                           <item>Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. (1)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_1.1">
                     <id root="c4113fc6-faf2-4233-83d8-a4d5d868aa7a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>1.1 Hypothyroidism</title>
                     <text>
                        <paragraph>Liothyronine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.2">
                     <id root="c12cafe0-0163-4dc7-bdca-5ca710a2544d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>1.2 Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression</title>
                     <text>
                        <paragraph>Liothyronine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.3">
                     <id root="c2937076-9162-4af6-806c-b71d1c924c93"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>1.3 Thyroid Suppression Test</title>
                     <text>
                        <br/>
                        <paragraph>Liothyronine sodium tablets are indicated as a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.<br/>
                           <br/>
                           <br/>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <br/>
                        <list listType="unordered" styleCode="disc">
                           <item>Liothyronine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with liothyronine sodium tablets may induce hyperthyroidism <content styleCode="italics">[see Warnings and Precautions (5.4)].</content>
                           </item>
                           <item>Liothyronine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.</item>
                        </list>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="970a3e3b-ba2c-45d7-b3cc-bde3919ca173"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20210624"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Administer liothyronine sodium tablets orally once daily and individual dosage according to patient response and laboratory findings (2.1)</item>
                           <item>See full prescribing information for recommended dosage for hypothyroidism (2.2) TSH suppression in well-differentiated thyroid cancer (2.3) and for thyroid suppression test (2.4)</item>
                           <item>When switching a patient to liothyronine sodium tablets discontinue levothyroxine therapy and initiate liothyronine sodium tablets at a low dosage. Gradually increase the dose according to the patient’s response (2.5)</item>
                           <item>Adequacy of therapy determined with periodic monitoring of TSH and T3 levels as well as clinical status (2.6)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="659e7832-0ebd-439f-9d57-11ba3f5dc471"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.1 General Principles of Dosing</title>
                     <text>
                        <paragraph>The dose of liothyronine sodium tablets for hypothyroidism or pituitary Thyroid-Stimulating Hormone (TSH) suppression depends on a variety of factors including: the patient's age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, coadministered food and the specific nature of the condition being treated <content styleCode="italics">[see Dosage and Administration (2.2, 2.3, 2.4), Warnings and Precautions (5), and Drug Interactions (7)]</content>. Dosing must be individualized to account for these factors and dose adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters <content styleCode="italics">[see Dosage and Administration (2.4)]</content>.</paragraph>
                        <br/>
                        <paragraph>Administer liothyronine sodium tablets orally once daily.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="f2efb437-3634-4e51-b521-66910063e3c8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.2 Recommended Dosage for Hypothyroidism</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph>The recommended starting dosage is 25 mcg orally once daily. Increase the dose by 25 mcg daily every 1 or 2 weeks, if needed. The usual maintenance dose is 25 mcg to 75 mcg once daily.</paragraph>
                        <paragraph>For elderly patients or patients with underlying cardiac disease, start with liothyronine sodium tablets <br/> 5 mcg once daily and increase by 5 mcg increments at the recommended intervals. </paragraph>
                        <paragraph>Serum TSH is not a reliable measure of liothyronine sodium tablets dose adequacy in patients with secondary or tertiary hypothyroidism and should not be used to monitor therapy. Use the serum T3 level to monitor adequacy of therapy in this patient population.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients</content>
                        </paragraph>
                        <paragraph>The recommended starting dosage is 5 mcg once daily, with a 5 mcg increase every 3 to 4 days until the desired response is achieved. Infants a few months old may require 20 mcg once daily for maintenance. At 1 year of age, 50 mcg once daily may be required. Above 3 years of age, the full adult dosage may be necessary <content styleCode="italics">[see Use in Specific Populations (8.4)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Newborns (0 to 3 months) at Risk for Cardiac Failure:</content>
                        </paragraph>
                        <paragraph>Consider a lower starting dose in infants at risk for cardiac failure. Increase the dose as needed based on clinical and laboratory response.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients at Risk for Hyperactivity:</content>
                        </paragraph>
                        <paragraph>To minimize the risk of hyperactivity in pediatric patients, start at one-fourth the recommended full replacement dose, and increase on a weekly basis by one-fourth the full recommended replacement dose until the full recommended replacement dose is reached.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pregnancy</content>
                        </paragraph>
                        <paragraph>Preexisting Hypothyroidism: Thyroid hormone dose requirements may increase during pregnancy. Measure serum TSH and free-T4 as soon as pregnancy is confirmed and, at minimum, during each trimester of pregnancy. In patients with primary hypothyroidism, maintain serum TSH in the trimester-specific reference range. For patients with serum TSH above the normal trimester-specific range, increase the dose of thyroid hormone and measure TSH every 4 weeks until a stable dose is reached and serum TSH is within the normal trimester-specific range. Reduce thyroid hormone dosage to pre-pregnancy levels immediately after delivery and measure serum TSH levels 4 to 8 weeks postpartum to ensure thyroid hormone dose is appropriate.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="f0387bfb-f9db-4b23-bab1-a249ce06c935"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.3 Recommended Dosage for TSH Suppression in Well-Differentiated Thyroid Cancer</title>
                     <text>
                        <paragraph>The dose of liothyronine sodium tablets should target TSH levels within the desired therapeutic range. This may require higher doses, depending on the target level for TSH suppression.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.4">
                     <id root="f9dc1f09-9be6-4a5c-ad69-cb81e37b29ce"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.4 Recommended Dosage for Thyroid Suppression Test</title>
                     <text>
                        <paragraph>The recommended dose is 75 mcg to 100 mcg daily for 7 days, with radioactive iodine uptake being determined before and after the 7 day administration of liothyronine sodium tablets. If thyroid function is normal, the radioiodine uptake will drop significantly after treatment. A 50% or greater suppression of uptake indicates a normal thyroid-pituitary axis.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.5">
                     <id root="f0172061-a18b-4a97-8e2d-adeca7f7239c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.5 Switching from Levothyroxine to Liothyronine Sodium Tablets</title>
                     <text>
                        <paragraph>Liothyronine sodium has a rapid onset of action and residual effects of the other thyroid preparation may persist for the first several weeks after initiating liothyronine sodium tablets therapy. When switching a patient to liothyronine sodium tablets, discontinue levothyroxine therapy and initiate liothyronine sodium tablets at a low dosage. Gradually increase the liothyronine sodium tablets, dose according to the patient's response.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.6">
                     <id root="40c39f25-f961-4ac9-94ba-b75b3d7bb808"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.6 Monitoring TSH and Triiodothyronine (T3) Levels</title>
                     <text>
                        <paragraph>Assess the adequacy of therapy by periodic assessment of laboratory tests and clinical evaluation. Persistent clinical and laboratory evidence of hypothyroidism despite an apparent adequate replacement dose of liothyronine sodium tablets may be evidence of inadequate absorption, poor compliance, drug interactions, or a combination of these factors.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph>In adult patients with primary hypothyroidism, monitor serum TSH periodically after initiation of the therapy or any change in dose. To check the immediate response to therapy before the TSH has had a chance to respond or if your patient’s status needs to be assessed prior to that point, measurement of total T3 would be most appropriate. In patients on a stable and appropriate replacement dose, evaluate clinical and biochemical response every 6 to 12 months and whenever there is a change in the patient’s clinical status.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatrics</content>
                        </paragraph>
                        <paragraph>In pediatric patients with hypothyroidism, assess the adequacy of replacement therapy by measuring serum TSH and T3 levels. For pediatric patients three years of age and older, the recommended monitoring is every 3 to 12 months thereafter, following dose stabilization until growth and puberty are completed. Poor compliance or abnormal values may necessitate more frequent monitoring. Perform routine clinical examination, including assessment of development, mental and physical growth, and bone maturation, at regular intervals.</paragraph>
                        <paragraph>While the general aim of therapy is to normalize the serum TSH level, TSH may not normalize in some patients due to <content styleCode="italics">in utero </content>hypothyroidism causing a resetting of pituitary-thyroid feedback. Failure of the serum TSH to decrease below 20 IU per liter after initiation of liothyronine sodium tablets therapy may indicate the child is not receiving adequate therapy. Assess compliance, dose of medication administered, and method of administration prior to increasing the dose of liothyronine sodium tablets <content styleCode="italics">[see Warnings and Precautions (5.1) </content>and <content styleCode="italics">Use in Specific Populations (8.4)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Secondary and Tertiary Hypothyroidism</content>
                        </paragraph>
                        <paragraph>Monitor serum T3 levels and maintain in the normal range.<content styleCode="bold"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="026e08a5-3e3c-45d8-b27e-3bd375b062c2"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Tablets (circular, white to off-white) available as follows:</paragraph>
                  <paragraph>• 5 mcg: debossed ‘589’ on one side and plain on other side</paragraph>
                  <paragraph>• 25 mcg: debossed ‘590’ on one side and breakline on other side</paragraph>
                  <paragraph>• 50 mcg: debossed ‘591’ on one side and breakline on other side</paragraph>
               </text>
               <effectiveTime value="20231003"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <paragraph>Tablets: 5 mcg, 25 mcg, 50 mcg (3)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="bae3585f-3809-4ca5-a6f3-d6e1ab6e9ba3"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Liothyronine sodium tablets are contraindicated in patients with uncorrected adrenal insufficiency <content styleCode="italics">[see Warnings and Precautions (5.3)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20210624"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Uncorrected adrenal cortical insufficiency (4)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="2171731b-bbdf-4e4f-b7e7-cec1f432be3c"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20210624"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease: Initiate liothyronine sodium tablets at less than the full replacement dose because of the increased risk of cardiac adverse reactions, including atrial fibrillation (2.3, 5.1, 8.5)</item>
                           <item>Myxedema coma: Do not use oral thyroid hormone drug products to treat myxedema coma. (5.2)</item>
                           <item>Acute adrenal crisis in patients with concomitant adrenal insufficiency: Treat with replacement glucocorticoids prior to initiation of liothyronine sodium tablets treatment (5.3)</item>
                           <item>Prevention of hyperthyroidism or incomplete treatment of hypothyroidism: Proper dose titration and careful monitoring is critical to prevent the persistence of hypothyroidism or the development of hyperthyroidism. (5.4)</item>
                           <item>Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy (5.5)</item>
                           <item>Decreased bone mineral density associated with thyroid hormone over-replacement: Over-replacement can increase bone resorption and decrease bone mineral density. Give the lowest effective dose (5.6)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="b846bcfa-82f8-46cd-aadd-d559be07c285"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.1 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease</title>
                     <text>
                        <paragraph>Overtreatment with thyroid hormone may cause an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias, particularly in patients with cardiovascular disease and in elderly patients. Initiate liothyronine sodium tablets therapy in this population at lower doses than those recommended in younger individuals or in patients without cardiac disease <content styleCode="italics">[see Dosage and Administration (2.3) and Use in Specific Populations (8.5)].</content>
                        </paragraph>
                        <paragraph>Monitor for cardiac arrhythmias during surgical procedures in patients with coronary artery disease receiving suppressive liothyronine sodium tablets therapy. Monitor patients receiving concomitant liothyronine sodium tablets and sympathomimetic agents for signs and symptoms of coronary insufficiency. If cardiovascular symptoms develop or worsen, reduce or withhold the liothyronine sodium tablets dose for one week and restart at a lower dose.<content styleCode="bold"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="c9419e32-2ac5-4734-ac9e-13b993c996a0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.2 Myxedema Coma</title>
                     <text>
                        <paragraph>Myxedema coma is a life-threatening emergency characterized by poor circulation and hypometabolism, and may result in unpredictable absorption of thyroid hormone from the gastrointestinal tract. Use of oral thyroid hormone drug products is not recommended to treat myxedema coma. Administer thyroid hormone products formulated for intravenous administration to treat myxedema coma.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="12692904-b5f2-4f1e-a074-3bbe30f49467"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.3 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency</title>
                     <text>
                        <paragraph>Thyroid hormone increases metabolic clearance of glucocorticoids. Initiation of thyroid hormone therapy prior to initiating glucocorticoid therapy may precipitate an acute adrenal crisis in patients with adrenal insufficiency. Treat patients with adrenal insufficiency with replacement glucocorticoids prior to initiating treatment with liothyronine sodium tablets <content styleCode="italics">[see Contraindications (4)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="3eaa28cc-1f31-47e4-a5ca-a81a8cb3b019"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.4 Prevention of Hyperthyroidism or Incomplete Treatment of Hypothyroidism</title>
                     <text>
                        <paragraph>Liothyronine sodium tablets have a narrow therapeutic index. Over- or undertreatment with liothyronine sodium tablets may have negative effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, emotional state, gastrointestinal function, and on glucose and lipid metabolism. Titrate the dose of liothyronine sodium tablets carefully and monitor response to titration to avoid these effects <content styleCode="italics">[see Dosage and Administration (2.4)]. </content>Monitor for the presence of drug or food interactions when using liothyronine sodium tablets and adjust the dose as necessary <content styleCode="italics">[see Drug Interactions (7) and Clinical Pharmacology (12.3)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="d2dcfac4-8ea6-4aad-9180-52f5e8f40da9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.5 Worsening of Diabetic Control</title>
                     <text>
                        <paragraph>Addition of thyroid hormone therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing liothyronine sodium tablets <content styleCode="italics">[see Drug Interactions (7.2)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.6">
                     <id root="a5498d97-1041-4537-872b-f5532eb0b26f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement</title>
                     <text>
                        <paragraph>Increased bone resorption and decreased bone mineral density may occur as a result of thyroid hormone over-replacement, particularly in post-menopausal women. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase, and suppressed serum parathyroid hormone levels. Administer the minimum dose of liothyronine sodium tablets that achieves the desired clinical and biochemical response to mitigate against this risk.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="52eb870c-278a-4670-97e0-f036c879ea37"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Adverse reactions associated with liothyronine sodium therapy are primarily those of hyperthyroidism due to therapeutic overdosage <content styleCode="italics">[see Warnings and Precautions (5.4) and Overdosage (10)]</content>. </paragraph>
                  <paragraph>They include the following:</paragraph>
                  <paragraph>
                     <content styleCode="italics">General</content>: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating</paragraph>
                  <paragraph>
                     <content styleCode="italics">Central nervous system</content>: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia</paragraph>
                  <paragraph>
                     <content styleCode="italics">Musculoskeletal</content>: tremors, muscle weakness and cramps</paragraph>
                  <paragraph>
                     <content styleCode="italics">Cardiovascular</content>: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest</paragraph>
                  <paragraph>
                     <content styleCode="italics">Respiratory</content>: dyspnea</paragraph>
                  <paragraph>
                     <content styleCode="italics">Gastrointestinal</content>: diarrhea, vomiting, abdominal cramps, elevations in liver function tests</paragraph>
                  <paragraph>
                     <content styleCode="italics">Dermatologic</content>: hair loss, flushing</paragraph>
                  <paragraph>
                     <content styleCode="italics">Endocrine</content>: decreased bone mineral density</paragraph>
                  <paragraph>
                     <content styleCode="italics">Reproductive</content>: menstrual irregularities, impaired fertility</paragraph>
                  <paragraph>
                     <content styleCode="underline">Adverse Reactions in Pediatric Patients</content>
                  </paragraph>
                  <paragraph>Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in pediatric patients receiving thyroid replacement therapy. Overtreatment may result in craniosynostosis in infants and premature closure of the epiphyses in pediatric patients with resultant compromised adult height.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity Reactions</content>
                  </paragraph>
                  <paragraph>Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various gastrointestinal symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness and wheezing.</paragraph>
               </text>
               <effectiveTime value="20210624"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions for liothyronine sodium tablets are primarily those of hyperthyroidism due to therapeutic overdosage: arrhythmias, myocardial infarction, dyspnea, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash (6)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">Sun Pharmaceutical Industries, Inc. at 1-800-818-4555 or FDA at 1-800-FDA-1088 or <content styleCode="italics">
                                 <content styleCode="underline">www.fda.gov/medwatch</content>
                              </content>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="db5b205e-9d59-4317-872b-3d3e4a62093a"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20231003"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to liothyronine sodium tablets (7)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_7.1">
                     <id root="f008044f-51ae-4381-a97e-a00eca00c051"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics</title>
                     <text>
                        <paragraph>Many drugs can exert effects on thyroid hormone pharmacokinetics (e.g. absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to liothyronine sodium tablets (see Tables 1 – 4).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1: Drugs That May Decrease T3 Absorption (Hypothyroidism)</content>
                        </paragraph>
                        <table width="976.22" cellspacing="0" cellpadding="0">
                           <colgroup>
                              <col width="21.5258855585831%"/>
                              <col width="78.4741144414169%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" colspan="2" align="justify" valign="top">Potential impact: Concurrent use may reduce the efficacy of liothyronine sodium tablets by binding and delaying or preventing absorption, potentially resulting in hypothyroidism.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold"> Drug or Drug Class</content>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Effect</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">Bile Acid<br/>Sequestrants<br/>-Colesevelam<br/>-Cholestyramine<br/>-Colestipol<br/>Ion Exchange Resins<br/>-Kayexalate<br/>-Sevelamer</td>
                                 <td styleCode="Rrule" align="justify" valign="middle">Bile acid sequestrants and ion exchange resins are known to decrease thyroid hormones absorption. Administer liothyronine sodium tablets at least 4 hours prior to these drugs or monitor thyrotropin-stimulating hormone (TSH) levels.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold"> Table 2: Drugs That May Alter Triiodothyronine (T3) Serum Transport Without Affecting Free Thyroxine (FT4) Concentration (Euthyroidism)</content>
                        </paragraph>
                        <table width="976.22" cellspacing="0" cellpadding="0">
                           <colgroup>
                              <col width="21.5258855585831%"/>
                              <col width="78.4741144414169%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">Drug or Drug Class</content>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="top">
                                    <content styleCode="bold">Effect</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Clofibrate<br/>Estrogen-containing<br/>oral contraceptives<br/>Estrogens (oral)<br/>Heroin / Methadone<br/>5-Fluorouracil<br/>Mitotane<br/>Tamoxifen</td>
                                 <td styleCode="Rrule" valign="middle">These drugs may increase serum thyroxine-binding globulin (TBG) concentration.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Androgens / Anabolic<br/>Steroids<br/>Asparaginase<br/>Glucocorticoids<br/>Slow-Release<br/>Nicotinic Acid</td>
                                 <td styleCode="Rrule" valign="middle">These drugs may decrease serum TBG concentration.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Salicylates (&gt;2 g/day)</td>
                                 <td styleCode="Rrule" align="justify" valign="top">Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="justify" valign="top">Other drugs:<br/>Carbamazepine<br/>Furosemide (&gt;80 mg<br/>IV)<br/>Heparin<br/>Hydantoins<br/>Non-Steroidal Antiinflammatory Drugs<br/>- Fenamates</td>
                                 <td styleCode="Rrule" align="justify" valign="middle">These drugs may cause protein binding site displacement. Furosemide has been shown to inhibit the protein binding of T4 to TBG and albumin, causing an increased free-T4 fraction in serum. Furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower the total T4 level. Phenytoin and carbamazepine reduce serum protein binding of thyroid hormones, and total and FT4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid. Closely monitor thyroid hormone parameters.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold"> Table 3: Drugs That May Alter Hepatic Metabolism of Thyroid hormones</content>
                        </paragraph>
                        <table width="976.22" cellspacing="0" cellpadding="0">
                           <colgroup>
                              <col width="21.5258855585831%"/>
                              <col width="78.4741144414169%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" colspan="2" align="justify" valign="top">Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of thyroid hormones, resulting in increased liothyronine sodium requirements.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold"> Drug or Drug Class</content>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="top">
                                    <content styleCode="bold">Effect</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">Phenobarbital<br/>Rifampin</td>
                                 <td styleCode="Rrule" align="justify" valign="middle">Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5'-diphospho-glucuronosyltransferase (UGT) and leads to a lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism. Rifampin has been shown to accelerate the metabolism of thyroid hormones.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold"> Table 4: Drugs That May Decrease Conversion of T4 to T3</content>
                        </paragraph>
                        <table width="976.22" cellspacing="0" cellpadding="0">
                           <colgroup>
                              <col width="21.5258855585831%"/>
                              <col width="78.4741144414169%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" colspan="2" align="justify" valign="top">Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels. However, serum T4 levels are usually normal but may occasionally be slightly increased.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold"> Drug or Drug Class</content>
                                 </td>
                                 <td styleCode="Rrule" align="center" valign="top">
                                    <content styleCode="bold">Effect</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Beta-adrenergic<br/>antagonists<br/>(e.g., Propranolol<br/>&gt;160 mg/day)</td>
                                 <td styleCode="Rrule" valign="middle">In patients treated with large doses of propranolol (&gt;160 mg/day), T3 and T4 levels change, TSH levels remain normal, and patients are clinically euthyroid. Actions of particular beta-adrenergic antagonists may be impaired when a hypothyroid patient is converted to the euthyroid state.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Glucocorticoids (e.g.,<br/>Dexamethasone<br/>≥4 mg/day)</td>
                                 <td styleCode="Rrule" valign="middle">Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (see above).</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">Other drugs:<br/>Amiodarone</td>
                                 <td styleCode="Rrule" valign="middle">Amiodarone inhibits peripheral conversion of levothyroxine (T4) to triiodothyronine (T3) and may cause isolated biochemical changes (increase in serum free-T4, and decreased or normal free-T3) in clinically euthyroid patients.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20231003"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.3">
                     <id root="deb28f09-5d64-4dc4-8d90-acb3c7ac9471"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.3 Oral Anticoagulants</title>
                     <text>
                        <paragraph>Liothyronine sodium increases the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the liothyronine sodium dose is increased. Closely monitor coagulation tests to permit appropriate and timely dosage adjustments.</paragraph>
                     </text>
                     <effectiveTime value="20231003"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.4">
                     <id root="2eb37e41-624c-4633-9517-9bea5b6d3029"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.4 Digitalis Glycosides</title>
                     <text>
                        <paragraph>Liothyronine sodium may reduce the therapeutic effects of digitalis glycosides. Serum digitalis glycoside levels may be decreased when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.5">
                     <id root="a4f04183-5f70-4855-b747-0d531254b817"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.5 Antidepressant Therapy</title>
                     <text>
                        <paragraph>Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and liothyronine sodium may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. Toxic effects may include increased risk of cardiac arrhythmias and central nervous system stimulation. Liothyronine sodium may accelerate the onset of action of tricyclics. Administration of sertraline in patients stabilized on liothyronine sodium may result in increased liothyronine sodium requirements.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.6">
                     <id root="19fb2a25-80eb-4bd0-a518-2fdd22fc0427"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.6 Ketamine</title>
                     <text>
                        <paragraph>Concurrent use of ketamine and liothyronine sodium may produce marked hypertension and tachycardia. Closely monitor blood pressure and heart rate in these patients.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.7">
                     <id root="a0b9fa29-f7fe-40b4-9bb8-70be4274e55b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.7 Sympathomimetics</title>
                     <text>
                        <paragraph>Concurrent use of sympathomimetics and liothyronine sodium may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.8">
                     <id root="48de1834-7864-43a1-a18f-d7b712179283"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.8 Tyrosine-Kinase Inhibitors</title>
                     <text>
                        <paragraph>Concurrent use of tyrosine-kinase inhibitors such as imatinib may cause hypothyroidism. Closely monitor TSH levels in such patients.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.9">
                     <id root="b6c46e57-68e2-417d-a456-bcd5d60ee9a5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.9 Drug-Laboratory Test Interactions</title>
                     <text>
                        <paragraph>Consider changes in TBG concentration when interpreting T4 and T3 values. Measure and evaluate unbound (free) hormone in this circumstance. Pregnancy, infectious hepatitis, estrogens, estrogen-containing oral contraceptives, and acute intermittent porphyria increase TBG concentrations. Nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, androgens and corticosteroids decrease TBG concentration. Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="6547c613-1650-4526-9aab-ddc232e4ae04"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20210624"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Pregnancy may require the use of higher doses of thyroid hormone (2.2, 8.1)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_8.1">
                     <id root="626e0b27-0ff1-429f-9abe-42ec80a29c6b"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Experience with liothyronine use in pregnant women, including data from postmarketing studies, have not reported increased rates of major birth defects or miscarriages <content styleCode="italics">(see Data). </content>There are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. Since TSH levels may increase during pregnancy, TSH should be monitored and liothyronine sodium dosage adjusted during pregnancy <content styleCode="italics">(see Clinical Considerations)</content>. There are no animal studies conducted with liothyronine during pregnancy. Liothyronine sodium tablets should not be discontinued during pregnancy and hypothyroidism diagnosed during pregnancy should be promptly treated.</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-associated maternal and/or embryo/fetal risk</content>
                        </paragraph>
                        <paragraph>Maternal hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, gestational hypertension, pre-eclampsia, stillbirth, and premature delivery. Untreated maternal hypothyroidism may have an adverse effect on fetal neurocognitive development.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Dose adjustments during pregnancy and the postpartum period</content>
                        </paragraph>
                        <paragraph>Pregnancy may increase liothyronine sodium requirements. Serum TSH levels should be monitored and the liothyronine sodium dosage adjusted during pregnancy. Since postpartum TSH levels are similar to preconception values, the liothyronine sodium dosage should return to the pre-pregnancy dose immediately after delivery <content styleCode="italics">[see Dosage and Administration (2.3)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Human Data</content>
                        </paragraph>
                        <paragraph>Liothyronine is approved for use as a replacement therapy for hypothyroidism. Data from postmarketing studies have not reported increased rates of fetal malformations, miscarriages, or other adverse maternal or fetal outcomes associated with liothyronine use in pregnant women.<content styleCode="bold"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="70fb6b6a-0c74-4a99-be21-9887384c0826"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Limited published studies report that liothyronine is present in human milk. However, there is insufficient information to determine the effects of liothyronine on the breastfed infant and no available information on the effects of liothyronine on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for liothyronine sodium and any potential adverse effects on the breastfed infant from liothyronine sodium or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="d3817866-1988-4a74-97b6-fba607f4de1d"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The initial dose of liothyronine sodium varies with age and body weight. Dosing adjustments are based on an assessment of the individual patient’s clinical and laboratory parameters <content styleCode="italics">[see Dosage and Administration (2.3, 2.4)].</content>
                        </paragraph>
                        <paragraph>In pediatric patients in whom a diagnosis of permanent hypothyroidism has not been established, discontinue thyroid hormone for a trial period, but only after the child is at least 3 years of age. Obtain serum TSH, T4, and T3 levels at the end of the trial period, and use laboratory test results and clinical assessments to guide diagnosis and treatment, if warranted <content styleCode="italics">[see Dosage and Administration (2.6)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Congenital Hypothyroidism</content>
                           <content styleCode="italics">[see Dosage and Administration (2.2, 2.6)]</content>
                        </paragraph>
                        <paragraph>Rapid restoration of normal serum T4 concentrations is essential for preventing the adverse effects of congenital hypothyroidism on intellectual development as well as on overall physical growth and maturation. Therefore, initiate thyroid hormone immediately upon diagnosis. Thyroid hormone is generally continued for life in these patients.</paragraph>
                        <paragraph>Closely monitor infants during the first 2 weeks of thyroid hormone therapy for cardiac overload, arrhythmias, and aspiration from avid suckling.</paragraph>
                        <paragraph>Closely monitor patients to avoid undertreatment or overtreatment. Undertreatment may have deleterious effects on intellectual development and linear growth. Overtreatment is associated with craniosynostosis in infants, may adversely affect the tempo of brain maturation, and may accelerate the bone age and result in premature epiphyseal closure and compromised adult stature <content styleCode="italics">[see Dosage and Administration (2.6)</content> and <content styleCode="italics">Adverse Reactions (6)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Acquired Hypothyroidism in Pediatric Patients</content>
                        </paragraph>
                        <paragraph>Closely monitor patients to avoid undertreatment and overtreatment. Undertreatment may result in poor school performance due to impaired concentration and slowed mentation and in reduced adult height. Overtreatment may accelerate the bone age and result in premature epiphyseal closure and compromised adult stature.</paragraph>
                        <paragraph>Treated children may manifest a period of catch-up growth, which may be adequate in some cases to normalize adult height. In children with severe or prolonged hypothyroidism, catch-up growth may not be adequate to normalize adult height <content styleCode="italics">[see Adverse Reactions (6)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="771a49e4-8579-48c4-9ad8-f1a980755971"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Because of the increased prevalence of cardiovascular disease among the elderly, initiate liothyronine sodium tablets at less than the full replacement dose <content styleCode="italics">[see Dosage and Administration (2.3) and Warnings and Precautions (5.1)]</content>. Atrial arrhythmias can occur in elderly patients. Atrial fibrillation is the most common of the arrhythmias observed with thyroid hormone overtreatment in the elderly.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="0ed29a51-a723-4652-949b-6eded466b33e"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>The signs and symptoms of overdosage are those of hyperthyroidism <content styleCode="italics">[see Warnings and Precautions (5.4)</content> and <content styleCode="italics">Adverse Reactions (6)].</content> In addition, confusion and disorientation may occur. Cerebral embolism, seizure, shock, coma, and death have been reported. Symptoms may not necessarily be evident or may not appear until several days after ingestion.</paragraph>
                  <paragraph>Reduce the liothyronine sodium dose or temporarily discontinued if signs or symptoms of overdosage occur. Initiate appropriate supportive treatment as dictated by the patient’s medical status.</paragraph>
                  <paragraph>For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org.</paragraph>
               </text>
               <effectiveTime value="20230628"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="53e1703c-48a8-4758-9e4d-fe678fdcbff6"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Liothyronine sodium tablets, USP contain the active ingredient, liothyronine (L-triiodothyronine or LT<sub>3</sub>), a synthetic form of a thyroid hormone liothyronine in sodium salt form. It is chemically designated as</paragraph>
                  <paragraph>
                     <br/> L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-, monosodium salt. The molecular formula, molecular weight and structural formula of liothyronine sodium are given below.</paragraph>
                  <paragraph>
                     <content>
                        <renderMultiMedia referencedObject="MM1"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content>C</content>
                     <sub>15</sub>
                     <content>H</content>
                     <sub>11</sub>
                     <content>I</content>
                     <sub>3</sub>
                     <content>NNaO</content>
                     <sub>4   </sub>
                     <content>M.W.672.96</content>
                  </paragraph>
                  <paragraph>Liothyronine sodium tablets, USP contain liothyronine sodium, USP equivalent to liothyronine in 5 mcg, 25 mcg, and 50 mcg. Inactive ingredients consist of corn starch, croscarmellose sodium, gelatin type B, magnesium stearate, mannitol, and microcrystalline cellulose.</paragraph>
               </text>
               <effectiveTime value="20231003"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>liothyronine-structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="liothyronine-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="cffdc661-969e-4b09-8d5a-30684fe55210"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20210624"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="3a749d6a-3310-4de6-b5e5-7a60b92a1640"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins.</paragraph>
                        <paragraph>The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.2">
                     <id root="0d3a9571-385a-4663-8948-627397cfe567"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The onset of activity of liothyronine sodium occurs within a few hours. Maximum pharmacologic response occurs within 2 or 3 days.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="03451e8e-2bea-4925-902f-b041a92d9578"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>T3 is almost totally absorbed, 95 percent in 4 hours. The hormones contained in the natural preparations are absorbed in a manner similar to the synthetic hormones.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Liothyronine sodium (T3) is not firmly bound to serum protein. The higher affinity of levothyroxine (T4) for both thyroid-binding globulin and thyroid-binding prealbumin as compared to triiodothyronine (T3) partially explains the higher serum levels and longer half-life of the former hormone. Both protein-bound hormones exist in reverse equilibrium with minute amounts of free hormone, the latter accounting for the metabolic activity.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>Metabolism</paragraph>
                        <paragraph>The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately 80% of circulating T3 is derived from peripheral T4 by monodeiodination. The liver is the major site of degradation for both T4 and T3. T3 is further deiodinated to diiodothyronine. Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation.</paragraph>
                        <paragraph>Excretion</paragraph>
                        <paragraph>Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the colon unchanged and is eliminated in the feces. The biological half-life is about 2-1/2 days.</paragraph>
                     </text>
                     <effectiveTime value="20210624"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="28c5beb0-e9fb-43ba-b081-eec42e23457e"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20230629"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="dbe4a449-77fa-4074-ae9f-0d747047f5b1"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Animal studies have not been performed to evaluate the carcinogenic potential, mutagenic potential or effects on fertility of liothyronine sodium.</paragraph>
                     </text>
                     <effectiveTime value="20230629"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="9149489c-f487-4ed8-9549-74eabb0b689e"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Product:    50090-7518</paragraph>
                  <paragraph>NDC:    50090-7518-0   100 TABLET in a BOTTLE</paragraph>
                  <paragraph>NDC:    50090-7518-1   90 TABLET in a BOTTLE</paragraph>
               </text>
               <effectiveTime value="20250312"/>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="0664ccc8-50b1-4444-a7a0-fca48fcf807a"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Dosing and Administration</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Instruct patients that liothyronine sodium tablets should only be taken as directed by their healthcare provider.</item>
                     <item>Instruct patients to notify their healthcare provider should they become pregnant or breastfeeding or are thinking of becoming pregnant, while taking liothyronine sodium tablets.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Important Information</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Inform patients that the liothyronine in liothyronine sodium tablets are intended to replace a hormone that is normally produced by the thyroid gland. Generally replacement therapy is to be taken for life.</item>
                     <item>Inform patients that liothyronine sodium tablets should not be used as a primary or adjunctive therapy in a weight control program.</item>
                     <item>Instruct patients to notify their healthcare provider if they are taking any other medications, including prescription and over-the-counter preparations.</item>
                     <item>Instruct patients to notify their healthcare provider of any other medical conditions, particularly heart disease, diabetes, clotting disorders, and adrenal or pituitary gland problems, as the dose of medications used to control these other conditions may need to be adjusted while taking liothyronine sodium tablets. If patents are taking anticoagulants (blood thinners), their clotting status should be checked frequently.</item>
                     <item>Instruct patients to notify their physician or dentist if they are taking liothyronine sodium tablets prior to any surgery.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Adverse Reactions</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Instruct patients to notify their healthcare provider if they experience any of the following symptoms: rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness, irritability, sleeplessness, tremors, change in appetite, weight gain or loss, vomiting, diarrhea, excessive sweating, heat intolerance, fever, changes in menstrual periods, hives or skin rash, or any other unusual medical event<content styleCode="italics"> [see Adverse Reactions (6)].</content>
                     </item>
                     <item>Inform patients that partial hair loss may occur rarely during the first few months of liothyronine sodium therapy; this is usually temporary <content styleCode="italics">[see Adverse Reactions (6)].</content>
                     </item>
                  </list>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Sun Pharmaceutical Industries, Inc.</content>
                  </paragraph>
                  <paragraph>Cranbury, NJ 08512</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Sun Pharmaceutical Ind. Ltd.</content>
                  </paragraph>
                  <paragraph>Survey No. 1012, Dadra-396 193,<br/>U.T. of D &amp; NH and Daman &amp; Diu, India.</paragraph>
                  <paragraph/>
                  <paragraph>ISS. 09/2023</paragraph>
                  <paragraph>5245289</paragraph>
               </text>
               <effectiveTime value="20231003"/>
            </section>
         </component>
         <component>
            <section>
               <id root="20b0da9a-4901-4db3-b73a-8232e64f0428"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>liothyronine sodium</title>
               <text>
                  <renderMultiMedia referencedObject="lbl500907518"/>
               </text>
               <effectiveTime value="20250312"/>
               <component>
                  <observationMedia ID="lbl500907518">
                     <text>Label Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="lbl500907518.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>